Science 37

Science 37’s Metasite™ is a virtual clinical trial site designed to eliminate physical proximity as a barrier, enabling patients to participate in clinical trials from any location. The Metasite™ has the recruiting power equivalent to 20 traditional sites and offers start-up times that are twice as fast as traditional site-based studies. It achieves three times greater diversity in patient recruitment and boasts a 96% patient retention rate, significantly higher than the 70% retention rate of traditional studies. Powered by a proprietary platform, the Metasite™ ensures uniform study orchestration and high-quality data collection. Science 37 employs in-house medical teams, telemedicine investigators, and mobile nurses with extensive experience in remote trial conduct, supporting a wide range of therapeutic areas including infectious disease, endocrinology, dermatology, cardiology, central nervous system, rare disease, oncology, and respiratory. The company offers a comprehensive range of trial activities, from patient recruitment and engagement to endpoint data collection and study visits. With over 150 trials launched, Science 37 has access to over 33 million patients and 34,000 physician providers. The Metasite™ model is recognized for accelerating recruitment and enrollment in remote and underrepresented communities and has been awarded the 2023 Frost & Sullivan Market Leadership Award in the global decentralized clinical trials industry. Science 37 emphasizes training healthcare staff on its platform to ensure ease of patient experience and data accuracy. The Metasite™ model has been successfully implemented in various case studies, including infectious disease and rare neurodegenerative disease trials. Additionally, Science 37’s central patient recruitment solution is performance-based, with more than 90% of program fees tied to performance outcomes. The Metasite™ also supports observational studies by enabling data collection from any device and ensuring protocol compliance through a unified platform.